Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from March 27, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on June 25, 2026 — +30.9% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$35.00 – $37.50Entry zone — fair-value band

$36.39Published — price the day we called it

$41.48Target — the price the thesis aimed for

$48.24Peak — highest point inside the window, not a realized return

$47.64Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 31 days.

At window close

+30.9%

realized, from the publication price to the last close inside the window

Peak gain

+32.6%

peak, from the publication price — not a realized return

S&P 500, same window

+16.1%

SPY over the identical days, dividend-adjusted

Window close

$47.64

last close inside the window, ended June 25, 2026

Peak price

$48.24

peak on June 25, 2026 — not a realized return

Days to target

The thesis — published March 27, 2026

Predicted growth

+14%

over the measurement window

Target price

$41.48

the price the thesis aimed for

Entry zone

$35.00 – $37.50

the fair-value band we waited for

Price at publication

$36.39

published March 27, 2026

Confidence

77%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

FDA approval of once-weekly insulin Awiqli refreshed the short-term story. The approval expands the insulin business and improves sentiment after recent pressure on the stock. Because the company is in defensive healthcare and not a cyclical growth name, the shares look set for a better rebound over the next three months compared with many oversold peers.

Primary drivers

Approval of once-weekly insulin gives a new, near-term focus
Strong diabetes and obesity drug lines offer steady demand
Healthcare-heavy business suits cautious market conditions
Recent selloff creates a clearer rebound opportunity

How it played out

NVO: target reached in 31 days

Lyra published NVO at $36.39 with an expected gain of 14% and a $41.48 target. The thesis pointed to the Awiqli approval, steady demand across diabetes and obesity drugs, a defensive healthcare business, and rebound potential after the recent selloff.

The shares reached the target in 31 days. They peaked at $48.24 on June 25, a gain of 32.6%, and ended the window at $47.64. The published thesis played out, and the market result exceeded the expected gain.

What happened during the window

On April 23, Novo Nordisk reported positive results from a trial of oral semaglutide in children and adolescents with type 2 diabetes. On June 7, the company reported that Wegovy pill prescriptions had passed three million.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals